Apotex Accuses Amgen Of Sham Patent Litigation

Law360, New York (October 6, 2015, 4:14 PM ET) -- Canadian generics maker Apotex Inc. fired back in Florida federal court Monday with counterclaims accusing Amgen Inc. of filing sham litigation alleging Apotex infringed two patents for blockbuster biologic Neulasta.



Amgen had sued Apotex in August over its proposed biosimilar to Neulasta, a drug that helps reduce the infection risk in people with non-bone-marrow-related cancers and low white blood cell counts as a result of chemotherapy. But Apotex said Monday that one patent will soon expire and that the other is invalid.



U.S. Patent No. 5,824,784,...

To view the full article, register now.